ELDN Stock Summary and Trading Ideas (Eledon Pharmaceuticals | NASDAQ:ELDN)

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals trades on the NASDAQ stock market under the symbol ELDN.

As of December 23, 2025, ELDN stock price declined to $1.57 with 362,663 million shares trading.

ELDN has a beta of 1.89, meaning it tends to be more sensitive to market movements. ELDN has a correlation of 0.11 to the broad based SPY ETF.

ELDN has a market cap of $117.80 million. This is considered a Micro Cap stock.

In the last 3 years, ELDN traded as high as $5.54 and as low as $1.07.

The top ETF exchange traded funds that ELDN belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

ELDN has underperformed the market in the last year with a price return of -64.0% while the SPY ETF gained +17.2%. ELDN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.6% and -1.3%, respectively, while the SPY returned +3.1% and +0.6%, respectively.

ELDN support price is $1.55 and resistance is $1.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELDN shares will trade within this expected range on the day.